About Curiox Biosystems

Curiox is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. Curiox has become a leader in the development and commercialization of innovative assay platforms based on its expertise in surface chemistry and engineering. Curiox’s vision is to accelerate the progress of life sciences, drug discovery and diagnostics through the miniaturization and improved automation of bioassays.

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange. The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.

Recently, Curiox has introduced Laminar Wash™ systems, automated cell processing platform enabling the most consistent and precise cell analysis and seen strong adoption and sales globally. The company has completed its Series B funding of US$15M in 2019 backed by a consortium of renowned venture capitalists of KB Investments, IMM Investments, Quad Investments, HB Investments, DayLI Investments, and SV Investments in Korea.

Management

Namyong Kim

Chief Executive Officer (CEO)

Dr. Namyong Kim

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays. Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange. The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.

Executive Vice President, CFO

Mr HongTae Jung

HongTae Jung is a KICPA (Korea Institute Certified Public Accountant). He worked for Samil PwC who is the biggest accounting firm in Korea for more than 13 years and he was appointed as the director. 

HongTae has experience with the small and medium companies who wanted for IPO in Korea stock market and helped them with their audit and other services. He has a lot of experience with big Korea companies who are listed on the Korea market and NYSE (New York Stock Exchange) as an auditor and adviser as well.

HongTae worked in India for PwC India for 2 years. He worked with the Korea companies in India and the companies who wanted to come into India market, for tax, accounting and regulations related work. 

Vice President of Sales and Marketing North America

David Choiniere

David Choiniere brings over 25 years of experience in the life sciences market, with extensive experience in flow cytometry, drug discovery, high throughput screening, and immunotherapy.

He formerly served as Vice President of Sales for IsoPlexis and, prior to that, Vice President of Sales for IntelliCyt Corporation (a Sartorius Company) for over ten years.


Board of Directors

CHAIRMAN AND MANAGING DIRECTOR,
ZICOM GROUP LIMITED

Mr Giok Lak Sim

Mr Sim is qualified as an accountant in 1967. He is Fellow of the Australian Society of Certified Practising Accountants and Fellow of the Institute of Certified Public Accountants, Singapore.

Mr Sim is a founder of Zicom Holdings Pte Ltd in 1978 and was appointed to the board on 5 April 1995. He has been Chairman and Managing Director of Zicom Group Limited and Executive Chairman of all subsidiaries. He is a true entrepreneur and savvy business executive with expertise in public accounting, corporate development, financial and industrial management and international trade.

Mr Sim also holds the position of a Chairman of BioBot Surgical Pte Ltd, a surgical robotic company and a director of HistoIndex Pte Ltd, a company involved in the development of histology indexing. He is the recipient of the Ernest & Young Entrepreneur of the Year (Industrial Products) 2008 award in Singapore.

EXECUTIVE DIRECTOR,
ZICOM GROUP LIMITED

Mr Kok Hwee Sim

Mr Sim is Executive director of ZGL and director of various group’s subsidiaries. He has a range of experiences in and is responsible for group corporate development, restructuring, business valuations and acquisitions.

Mr Sim received his Master of Financial Engineering degree from Columbia University and Bachelor of Industrial and Operations Engineering (Magna Cum Laude) degree from the University of Michigan.

Namyong Kim

CHIEF EXECUTIVE OFFICER (CEO),
CURIOX BIOSYSTEMS

Dr Namyong Kim

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays. Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

VP, IMM INVESTMENT

Ms Aleum Lee

Ms. Lee is currently working in IMM Investment. Having a Pharmaceutical major, is working as a bio-specialized investor and has recorded 8 IPO’s since joining IMM.

IMM Investment is one of the leading native Korea investment firm, focusing on venture capital, mezzanine, infrastructure and aircraft investments. IMM AUM has built up to USD 3.7bn, and has accumulated Exit IRR of 23.8%. 

Before joining IMM, Ms. Lee acted as an Bio/Pharmaceutical Analyst in several security companies and has been rewarded as best analyst for several times.   

She received her B.S and M.S in Pharmacology from Seoul National University.

MANAGING DIRECTOR, QUAD IM

Mr Youngtae Hong

Dr. Youngtae Hong is currently managing the PEF that is specifically dedicated to investing private venture companies as a Managing Director of QUAD Investment Management, Inc in Korea.

Before joining QUAD IM, he began his career in 2004 at ViroMed, a Korean biotech company as a research scientist. He was responsible for the first ex-vivo gene therapy clinical trial that is officially approved by Korean FDA and two clinical trials in the US with a plasmid-based therapeutic.

As a head of business development, he was involved in many types of business deals from a collaboration agreement to license-in or out agreements with domestic or foreign companies.

He received his BS in Microbiology and MS and PhD in Genetic Engineering from Seoul National University.